好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Virtual Reality as an Intervention for Chronic Pain in Multiple Sclerosis
Multiple Sclerosis
MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)
188
To assess the feasibility and efficacy of virtual reality (VR) as an intervention for chronic pain due to MS.
VR technology is emerging as a platform for clinical interventions. VR uses a head mounted display that enables users to be immersed in controlled 360° virtual environments. The psychological immersion of the VR environment has been found to be effective in relieving acute pain.  Here, we evaluated whether repeated immersive VR sessions could reduce the MS symptom of chronic pain.
The intervention consisted of 8 x 35-minute immersive VR sessions over the course of four weeks.  Acute change in pain was measured before and after each VR session using a visual analog (VAS). Response to the intervention was measured with change in PROMIS pain scales administered at baseline and intervention end. 
Participants were n=8 MS patients (n=7 RRMS, n=1 SPMS; 88% female; Mean 50.00 ±11.02 years, EDSS<7.0) with chronic disease-related pain. Feasibility was met with 87.5% of participants completing at least 50% of all sessions. Participants rated the VR platform as a highly acceptable and appealing format for intervention. The individual VR sessions reduced acute pain (VAS mean reduction of -0.92± 1.38) and chronic pain from baseline to intervention end (PROMIS pain mean reduction of -0.29± 2.75). At intervention end, 7/7 (100%) participants reported that they would use VR again.
Repeated sessions of immersive VR experiences are tolerable and feasible for individuals with MS, and may provide a non-pharmacological tool for chronic pain management.
Authors/Disclosures
Martin Malik
PRESENTER 		Martin Malik has nothing to disclose.
Michael Shaw Mr. Shaw has nothing to disclose.
Maria Palmeri (NYU Langone Health) Ms. Palmeri has nothing to disclose.
Leigh E. Charvet, PhD (NYU Langone) Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Johnson & Johnson. Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Springer Healthcare. Dr. Charvet has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for YBrain. Dr. Charvet has stock in Johnson&Johnson.